Objective: To study the effect of ultrashort wave therapy combined with antioxidant and neurotrophy therapy on nerve conduction function and serum cytokines in patients with diabetic peripheral neuropathy. Methods: A ...Objective: To study the effect of ultrashort wave therapy combined with antioxidant and neurotrophy therapy on nerve conduction function and serum cytokines in patients with diabetic peripheral neuropathy. Methods: A total of 128 patients who were diagnosed with DPN in South District of Guang'anmen Hospital of China Academy of Chinese Medical Sciences between May 2014 and February 2017 were selected as the research subjects and randomly divided into electrotherapy + drug group and routine drug group;the nerve conduction velocity as well as serum levels of nerve cytokines and inflammatory cytokines were measured before treatment and 8 weeks after treatment. Results: Median nerve and common peroneal nerve MNCV, median nerve and superficial peroneal nerve SNCV as well as serum CNTF, BDNF, SDF-1α, IGF-1, CAT and HO-1 levels of both groups 8 weeks after treatment were significantly higher than those before treatment while serum ICAM-1, TNF-α, IL-6, ET-1, MDA and 8-OHdG levels were significantly lower than those before treatment;median nerve and common peroneal nerve MNCV, median nerve and superficial peroneal nerve SNCV as well as serum CNTF, BDNF, SDF-1α, IGF-1, CAT and HO-1 levels of electrotherapy + drug group 8 weeks after treatment were significantly higher than those of routine drug group while serum ICAM-1, TNF-α, IL-6, ET-1, MDA and 8-OHdG levels were significantly lower than those of routine drug group. Conclusion: Ultrashort wave therapy combined with antioxidant and neurotrophy therapy for DPN can improve the nerve conduction function and neurotrophic state, and also inhibit the inflammatory response and oxidative stress response.展开更多
文摘Objective: To study the effect of ultrashort wave therapy combined with antioxidant and neurotrophy therapy on nerve conduction function and serum cytokines in patients with diabetic peripheral neuropathy. Methods: A total of 128 patients who were diagnosed with DPN in South District of Guang'anmen Hospital of China Academy of Chinese Medical Sciences between May 2014 and February 2017 were selected as the research subjects and randomly divided into electrotherapy + drug group and routine drug group;the nerve conduction velocity as well as serum levels of nerve cytokines and inflammatory cytokines were measured before treatment and 8 weeks after treatment. Results: Median nerve and common peroneal nerve MNCV, median nerve and superficial peroneal nerve SNCV as well as serum CNTF, BDNF, SDF-1α, IGF-1, CAT and HO-1 levels of both groups 8 weeks after treatment were significantly higher than those before treatment while serum ICAM-1, TNF-α, IL-6, ET-1, MDA and 8-OHdG levels were significantly lower than those before treatment;median nerve and common peroneal nerve MNCV, median nerve and superficial peroneal nerve SNCV as well as serum CNTF, BDNF, SDF-1α, IGF-1, CAT and HO-1 levels of electrotherapy + drug group 8 weeks after treatment were significantly higher than those of routine drug group while serum ICAM-1, TNF-α, IL-6, ET-1, MDA and 8-OHdG levels were significantly lower than those of routine drug group. Conclusion: Ultrashort wave therapy combined with antioxidant and neurotrophy therapy for DPN can improve the nerve conduction function and neurotrophic state, and also inhibit the inflammatory response and oxidative stress response.
